![]() |
|
|
Department of Pharmacology and Toxicology, Institute of Pharmacy, University of Bonn, Bonn, Germany (C.T., O.W., U.V., K.M.); Division of Physical Biochemistry, National Institute for Medical Research, Mill Hill, London, United Kingdom (A.M., N.J.M.B.); and MRC Technology, Mill Hill, London, United Kingdom (S.L.)
An optimized assay for the binding of [3H]dimethyl-W84 to its allosteric site on M2 muscarinic receptors has been used to directly measure the affinities of allosteric ligands. Their potencies agree with those deduced indirectly by their modulation of the equilibrium binding and kinetics of [3H]N-methylscopolamine ([3H]NMS) binding to the orthosteric site. The affinities and cooperativities of orthosteric antagonists with [3H]dimethyl-W84 have also been quantitated. These affinities agree with those measured directly in a competition assay using [3H]NMS. All these data are compatible with the predictions of the allosteric ternary complex model. The association and dissociation kinetics of [3H]dimethyl-W84 are rapid but the estimate of its association rate constant is nevertheless comparable with that found for the orthosteric radioligand, [3H]NMS. This is unexpected, given that the allosteric site to which [3H]dimethyl-W84 binds is thought to be located on the external face of the receptor and above the [3H]NMS binding site that is buried within the transmembrane helices. The atypical allosteric ligands tacrine and 4,4'-bis-[(2,6-dichloro-benzyloxy-imino)-methyl]-1,1'-propane-1,3-diyl-bis-pyridinium dibromide (Duo3) inhibit [3H]dimethyl-W84 binding with the same potencies and comparably steep slope factors as found for inhibition of [3H]NMS binding. Tacrine and Duo3 decrease [3H]dimethyl-W84 affinity, not the number of binding sites. It is suggested that these atypical ligands either bind to the two known spatially separated allosteric sites on muscarinic receptors with positive cooperativity or their binding to the common allosteric site modulates receptor-receptor interactions such that homotropic positive cooperativity within a dimer or higher oligomer is generated.
Address correspondence to: Dr. Christian Tränkle, Department of Pharmacology and Toxicology, Institute of Pharmacy, University of Bonn, Gerhard-Domagk-Strasse 3, D-53121 Bonn, Germany. E-mail: traenkle{at}uni-bonn.de
This article has been cited by other articles:
![]() |
X.-P. Huang and J. Ellis Mutational Disruption of a Conserved Disulfide Bond in Muscarinic Acetylcholine Receptors Attenuates Positive Homotropic Cooperativity between Multiple Allosteric Sites and Has Subtype-Dependent Effects on the Affinities of Muscarinic Allosteric Ligands Mol. Pharmacol., March 1, 2007; 71(3): 759 - 768. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Lanzafame, P. M. Sexton, and A. Christopoulos Interaction Studies of Multiple Binding Sites on M4 Muscarinic Acetylcholine Receptors Mol. Pharmacol., August 1, 2006; 70(2): 736 - 746. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Prilla, J. Schrobang, J. Ellis, H.-D. Holtje, and K. Mohr Allosteric Interactions with Muscarinic Acetylcholine Receptors: Complex Role of the Conserved Tryptophan M2422Trp in a Critical Cluster of Amino Acids for Baseline Affinity, Subtype Selectivity, and Cooperativity Mol. Pharmacol., July 1, 2006; 70(1): 181 - 193. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Franco, V. Casado, J. Mallol, C. Ferrada, S. Ferre, K. Fuxe, A. Cortes, F. Ciruela, C. Lluis, and E. I. Canela The Two-State Dimer Receptor Model: A General Model for Receptor Dimers Mol. Pharmacol., June 1, 2006; 69(6): 1905 - 1912. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Fruchart-Gaillard, G. Mourier, C. Marquer, A. Menez, and D. Servent Identification of Various Allosteric Interaction Sites on M1 Muscarinic Receptor Using 125I-Met35-Oxidized Muscarinic Toxin 7 Mol. Pharmacol., May 1, 2006; 69(5): 1641 - 1651. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Whitehurst, N. Nazef, D. A. Annis, Y. Hou, D. M. Murphy, P. Spacciapoli, Z. Yao, M. R. Ziebell, C. C. Cheng, G. W. Shipps Jr., et al. Discovery and Characterization of Orthosteric and Allosteric Muscarinic M2 Acetylcholine Receptor Ligands by Affinity Selection-Mass Spectrometry J Biomol Screen, March 1, 2006; 11(2): 194 - 207. [Abstract] [PDF] |
||||
![]() |
C. Trankle, A. Dittmann, U. Schulz, O. Weyand, S. Buller, K. Johren, E. Heller, N. J. M. Birdsall, U. Holzgrabe, J. Ellis, et al. Atypical Muscarinic Allosteric Modulation: Cooperativity between Modulators and Their Atypical Binding Topology in Muscarinic M2 and M2/M5 Chimeric Receptors Mol. Pharmacol., December 1, 2005; 68(6): 1597 - 1610. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wess Allosteric Binding Sites on Muscarinic Acetylcholine Receptors Mol. Pharmacol., December 1, 2005; 68(6): 1506 - 1509. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-P. Huang, S. Prilla, K. Mohr, and J. Ellis Critical Amino Acid Residues of the Common Allosteric Site on the M2 Muscarinic Acetylcholine Receptor: More Similarities than Differences between the Structurally Divergent Agents Gallamine and Bis(ammonio)alkane-Type Hexamethylene-bis-[dimethyl-(3-phthalimidopropyl)ammonium]dibromide Mol. Pharmacol., September 1, 2005; 68(3): 769 - 778. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Avlani, L. T. May, P. M. Sexton, and A. Christopoulos Application of a Kinetic Model to the Apparently Complex Behavior of Negative and Positive Allosteric Modulators of Muscarinic Acetylcholine Receptors J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 1062 - 1072. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Lazareno, V. Dolezal, A. Popham, and N. J. M. Birdsall Thiochrome Enhances Acetylcholine Affinity at Muscarinic M4 Receptors: Receptor Subtype Selectivity via Cooperativity Rather than Affinity Mol. Pharmacol., January 1, 2004; 65(1): 257 - 266. [Abstract] [Full Text] [PDF] |
||||